 Meghan Jeffres
Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Hypersensitivity | 5 | 2021 | 83 | 3.090 |
Why?
| | Penicillins | 5 | 2021 | 50 | 2.530 |
Why?
| | Cefazolin | 3 | 2021 | 19 | 2.420 |
Why?
| | Education, Pharmacy | 7 | 2019 | 130 | 2.120 |
Why?
| | Anti-Bacterial Agents | 8 | 2021 | 1510 | 2.050 |
Why?
| | Schools, Pharmacy | 6 | 2019 | 52 | 1.940 |
Why?
| | Vancomycin | 4 | 2021 | 79 | 1.860 |
Why?
| | beta-Lactams | 3 | 2018 | 28 | 1.320 |
Why?
| | Faculty, Pharmacy | 5 | 2019 | 17 | 1.260 |
Why?
| | Antibiotic Prophylaxis | 3 | 2021 | 100 | 1.110 |
Why?
| | Career Mobility | 4 | 2017 | 66 | 1.050 |
Why?
| | Pharmacists | 5 | 2017 | 238 | 1.030 |
Why?
| | Career Choice | 4 | 2017 | 192 | 0.940 |
Why?
| | Pharmaceutical Services | 1 | 2022 | 79 | 0.810 |
Why?
| | Clindamycin | 1 | 2021 | 12 | 0.800 |
Why?
| | Hypersensitivity, Immediate | 1 | 2021 | 59 | 0.770 |
Why?
| | Students, Pharmacy | 4 | 2019 | 99 | 0.750 |
Why?
| | Play and Playthings | 2 | 2018 | 30 | 0.730 |
Why?
| | Liver Abscess, Pyogenic | 1 | 2019 | 1 | 0.710 |
Why?
| | Professional Role | 2 | 2017 | 153 | 0.700 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2019 | 39 | 0.690 |
Why?
| | Anaphylaxis | 1 | 2021 | 146 | 0.690 |
Why?
| | Kidney Diseases | 2 | 2017 | 439 | 0.660 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 67 | 0.660 |
Why?
| | Education, Medical | 2 | 2018 | 239 | 0.630 |
Why?
| | Video Games | 1 | 2018 | 22 | 0.630 |
Why?
| | Liability, Legal | 1 | 2018 | 39 | 0.630 |
Why?
| | Communicable Diseases | 1 | 2019 | 132 | 0.620 |
Why?
| | Malpractice | 1 | 2018 | 38 | 0.620 |
Why?
| | Methicillin Resistance | 2 | 2007 | 19 | 0.600 |
Why?
| | Pneumonia, Staphylococcal | 2 | 2007 | 17 | 0.590 |
Why?
| | Skin Tests | 1 | 2017 | 135 | 0.580 |
Why?
| | Curriculum | 3 | 2019 | 910 | 0.570 |
Why?
| | Cross Infection | 2 | 2007 | 205 | 0.500 |
Why?
| | Bacterial Infections | 1 | 2015 | 227 | 0.470 |
Why?
| | Motivation | 1 | 2018 | 506 | 0.470 |
Why?
| | Staphylococcus aureus | 2 | 2007 | 394 | 0.450 |
Why?
| | Staphylococcal Infections | 1 | 2017 | 346 | 0.450 |
Why?
| | Students | 1 | 2018 | 509 | 0.450 |
Why?
| | Educational Status | 1 | 2014 | 437 | 0.420 |
Why?
| | Health Personnel | 1 | 2018 | 588 | 0.420 |
Why?
| | Ciprofloxacin | 1 | 2011 | 24 | 0.400 |
Why?
| | Urinary Tract Infections | 1 | 2011 | 136 | 0.360 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 227 | 0.330 |
Why?
| | Humans | 25 | 2022 | 118972 | 0.290 |
Why?
| | Retrospective Studies | 10 | 2021 | 12978 | 0.280 |
Why?
| | Problem-Based Learning | 2 | 2019 | 82 | 0.260 |
Why?
| | Incidence | 3 | 2021 | 2424 | 0.240 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 302 | 0.230 |
Why?
| | Middle Aged | 9 | 2021 | 27617 | 0.220 |
Why?
| | Drug Storage | 1 | 2022 | 59 | 0.210 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 736 | 0.210 |
Why?
| | Drug Stability | 1 | 2022 | 153 | 0.210 |
Why?
| | Liver Diseases | 2 | 2016 | 282 | 0.210 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 175 | 0.200 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6561 | 0.200 |
Why?
| | Intraoperative Period | 1 | 2021 | 55 | 0.200 |
Why?
| | Venous Thromboembolism | 2 | 2016 | 234 | 0.200 |
Why?
| | Adult | 10 | 2021 | 31512 | 0.190 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 167 | 0.180 |
Why?
| | Kidney | 1 | 2007 | 1353 | 0.180 |
Why?
| | Temperature | 1 | 2022 | 622 | 0.180 |
Why?
| | United States | 3 | 2022 | 12555 | 0.170 |
Why?
| | Cohort Studies | 4 | 2019 | 5116 | 0.170 |
Why?
| | Administration, Intravenous | 1 | 2019 | 136 | 0.170 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 215 | 0.160 |
Why?
| | Male | 12 | 2021 | 57801 | 0.160 |
Why?
| | Surgical Wound Infection | 1 | 2021 | 251 | 0.160 |
Why?
| | Cephalosporins | 1 | 2018 | 27 | 0.160 |
Why?
| | Time Management | 1 | 2017 | 16 | 0.160 |
Why?
| | Female | 12 | 2021 | 61564 | 0.160 |
Why?
| | Universities | 2 | 2018 | 347 | 0.160 |
Why?
| | Hospital Mortality | 2 | 2015 | 814 | 0.150 |
Why?
| | Occupational Stress | 1 | 2017 | 34 | 0.150 |
Why?
| | Professional Competence | 1 | 2017 | 91 | 0.150 |
Why?
| | Administration, Oral | 1 | 2019 | 756 | 0.150 |
Why?
| | Aged | 5 | 2021 | 19657 | 0.140 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 95 | 0.140 |
Why?
| | Risk Factors | 5 | 2017 | 9000 | 0.140 |
Why?
| | Young Adult | 5 | 2018 | 10793 | 0.130 |
Why?
| | Cooperative Behavior | 1 | 2017 | 408 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 190 | 0.130 |
Why?
| | Hemorrhage | 2 | 2016 | 623 | 0.130 |
Why?
| | Treatment Failure | 1 | 2015 | 341 | 0.130 |
Why?
| | Educational Measurement | 2 | 2014 | 289 | 0.120 |
Why?
| | Interpersonal Relations | 1 | 2017 | 345 | 0.120 |
Why?
| | Length of Stay | 2 | 2016 | 1032 | 0.120 |
Why?
| | Health Care Costs | 1 | 2017 | 394 | 0.120 |
Why?
| | Patient Readmission | 1 | 2019 | 634 | 0.120 |
Why?
| | Inpatients | 1 | 2017 | 388 | 0.110 |
Why?
| | Anticoagulants | 2 | 2016 | 559 | 0.110 |
Why?
| | Cephalometry | 1 | 2012 | 28 | 0.110 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2012 | 28 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 1945 | 0.110 |
Why?
| | Clinical Protocols | 1 | 2013 | 238 | 0.110 |
Why?
| | Pharynx | 1 | 2012 | 53 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2019 | 9342 | 0.100 |
Why?
| | Data Collection | 1 | 2014 | 658 | 0.100 |
Why?
| | Drug Resistance, Microbial | 1 | 2011 | 67 | 0.100 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 4708 | 0.100 |
Why?
| | Logistic Models | 1 | 2015 | 1901 | 0.090 |
Why?
| | Prevalence | 1 | 2017 | 2326 | 0.090 |
Why?
| | Hyperglycemia | 1 | 2013 | 312 | 0.090 |
Why?
| | Physicians | 1 | 2018 | 794 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 499 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2674 | 0.080 |
Why?
| | Missouri | 1 | 2006 | 63 | 0.070 |
Why?
| | Biological Availability | 1 | 2006 | 126 | 0.070 |
Why?
| | Area Under Curve | 1 | 2006 | 296 | 0.070 |
Why?
| | Creatinine | 1 | 2007 | 491 | 0.070 |
Why?
| | Survival Analysis | 1 | 2006 | 1267 | 0.060 |
Why?
| | Adolescent | 3 | 2016 | 18480 | 0.050 |
Why?
| | Chronic Disease | 2 | 2016 | 1636 | 0.040 |
Why?
| | Employee Performance Appraisal | 1 | 2017 | 5 | 0.040 |
Why?
| | Work | 1 | 2017 | 18 | 0.040 |
Why?
| | Feedback | 1 | 2017 | 153 | 0.040 |
Why?
| | International Normalized Ratio | 1 | 2016 | 45 | 0.040 |
Why?
| | Diabetic Coma | 1 | 2013 | 1 | 0.030 |
Why?
| | Hypokalemia | 1 | 2013 | 31 | 0.030 |
Why?
| | Nevada | 1 | 2013 | 8 | 0.030 |
Why?
| | Hospitals, University | 1 | 2013 | 172 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 324 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 380 | 0.030 |
Why?
| | Dental Clinics | 1 | 2012 | 4 | 0.030 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2012 | 12 | 0.030 |
Why?
| | Longevity | 1 | 2013 | 151 | 0.030 |
Why?
| | Diabetic Ketoacidosis | 1 | 2013 | 168 | 0.020 |
Why?
| | Teaching Materials | 1 | 2011 | 26 | 0.020 |
Why?
| | Patient Safety | 1 | 2013 | 281 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 983 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2013 | 635 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3171 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1527 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4552 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3057 | 0.020 |
Why?
| | Sex Factors | 1 | 2012 | 1781 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4196 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1032 | 0.020 |
Why?
| | Blood Glucose | 1 | 2013 | 1939 | 0.020 |
Why?
| | Hospitalization | 1 | 2013 | 1785 | 0.020 |
Why?
| | Insulin | 1 | 2013 | 2162 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2174 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2013 | 3360 | 0.010 |
Why?
| | Child | 1 | 2012 | 19129 | 0.010 |
Why?
|
|
Jeffres's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|